$1.72
Live
Revenue is up for the last 2 quarters, 1.41M → 1.82M (in $), with an average increase of 22.7% per quarter
Netprofit is up for the last 6 quarters, -27.15M → -15.54M (in $), with an average increase of 12.2% per quarter
In the last 1 year, Seagen Inc has given 36.8% return, outperforming this stock by 35.1%
0.58%
Downside
Day's Volatility :7.06%
Upside
6.52%
31.4%
Downside
52 Weeks Volatility :56.62%
Upside
36.76%
Period | BOLT BIOTHERAPEUTICS INC | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 13.66% | 0.3% | -6.7% |
6 Months | 23.65% | -8.3% | -6.2% |
1 Year | 7.65% | -4.8% | -6.3% |
3 Years | -94.31% | 23.8% | 26.9% |
Market Capitalization | 69.2M |
Book Value | $4.17 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.15 |
Wall Street Target Price | 5.17 |
Profit Margin | 0.0% |
Operating Margin TTM | -1258.68% |
Return On Assets TTM | -21.69% |
Return On Equity TTM | -42.17% |
Revenue TTM | 6.7M |
Revenue Per Share TTM | 0.18 |
Quarterly Revenue Growth YOY | 124.6% |
Gross Profit TTM | 1.6M |
EBITDA | -83.1M |
Diluted Eps TTM | -2.15 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.86 |
EPS Estimate Next Year | -1.63 |
EPS Estimate Current Quarter | -0.46 |
EPS Estimate Next Quarter | -0.49 |
What analysts predicted
Upside of 200.58%
Sell
Neutral
Buy
BOLT BIOTHERAPEUTICS INC is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() BOLT BIOTHERAPEUTICS INC | 17.31% | 23.65% | 7.65% | -94.31% | -94.31% |
![]() Moderna, Inc. | -5.37% | -28.24% | -13.14% | 103.02% | 578.71% |
![]() Regeneron Pharmaceuticals, Inc. | -10.12% | -3.55% | 9.07% | 20.95% | 140.97% |
![]() Seagen, Inc. | -2.85% | 59.4% | 42.61% | 21.68% | 240.77% |
![]() Vertex Pharmaceuticals Incorporated | -4.35% | 4.3% | 22.83% | 15.12% | 110.67% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() BOLT BIOTHERAPEUTICS INC | NA | NA | NA | -1.86 | -0.42 | -0.22 | 0.0 | 4.17 |
![]() Moderna, Inc. | 11.22 | 11.22 | 0.0 | -1.83 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.72 | 19.72 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.53 | 26.53 | 0.41 | 13.64 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() BOLT BIOTHERAPEUTICS INC | Buy | $69.2M | -94.31% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $48.1B | 578.71% | 11.22 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $79.5B | 140.97% | 19.72 | 33.81% |
![]() Seagen, Inc. | Hold | $36.3B | 240.77% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.0B | 110.67% | 26.53 | 35.4% |
Vivo Capital, LLC
Sofinnova Ventures
Citadel Advisors Llc
Pivotal bioVenture Partners Investment Advisor LLC
Newtyn Management LLC
Samsara BioCapital, LLC
BOLT BIOTHERAPEUTICS INC’s price-to-earnings ratio stands at None
Read MoreBolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach combines an antibody that targets a tumor antigen with an immune stimulant that triggers an innate and adaptive immune response in the tumor microenvironment. These systemically-delivered Boltbody ISACs are designed to target tumor cells for elimination by myeloid cells, which are then activated and recruit the adaptive immune system in the anti-tumor response. This leads to the conversion of immunologically "cold" tumors to "hot" tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034, a Boltbody ISAC targeting CEA, and a pipeline of other immuno-oncology products.
Organization | BOLT BIOTHERAPEUTICS INC |
Employees | 94 |
CEO | Dr. Randall C. Schatzman Ph.D. |
Industry | Healthcare |
Presto Automation Inc
$2.77
-22.84%
D-MARKET ELECTRONIC SERVICES
$1.07
+2.88%
Mexico MSCI Capped ETF iShares
$60.27
-1.55%
Global X S&P Catholic Values Developed ex-US ETF
$27.78
-1.1%
IndexIQ ETF Trust - IQ Chaikin U.S. Small Cap ETF
$30.74
-0.65%
DFA Dimensional Internatl High Profitability ETF
$23.80
-1.16%
Precigen Inc
$1.22
+0.0%
EXSCIENTIA PLC
$7.72
-3.02%
ISHARES GEN-IMMUNOLOGY HLTH
$23.85
-0.75%